Controlled trial of ketanserin in hypertension.
Open Access
- 26 July 1985
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 20 (1), 37-40
- https://doi.org/10.1111/j.1365-2125.1985.tb02795.x
Abstract
We have completed a double-blind parallel group comparison of the 5-HT2 receptor antagonist ketanserin with placebo in 22 hypertensive patients. Ketanserin (20-40 mg twice daily) lowered sitting blood pressure more than placebo by 6.9 mm Hg systolic (NS), 13.1 mm Hg diastolic (P less than 0.05) and by 11.4 mm Hg mean arterial pressure (P less than 0.02). The fall in standing blood pressure was similar and we observed no first dose hypotensive effect. Ketanserin lowered the sitting heart rate by 11.1 beats/min (P less than 0.01). The drug was well tolerated.This publication has 10 references indexed in Scilit:
- Double-Blind Comparison of Ketanserin with Propranolol in Hypertensive PatientsJournal of Cardiovascular Pharmacology, 1985
- Haemodynamic and humoral responses to chronic ketanserin treatment in essential hypertension.Heart, 1984
- 5-HT, alpha-adrenoceptors, and blood pressure. Effects of ketanserin in essential hypertension and autonomic insufficiency.Hypertension, 1984
- Mechanism of antihypertensive action of ketanserin in man.BMJ, 1983
- Mechanism of antihypertensive action of ketanserin in man.BMJ, 1983
- Ketanserin, a novel 5‐hydroxytryptamine antagonist: monotherapy in essential hypertension.British Journal of Clinical Pharmacology, 1983
- Ketanserin in HypertensionActa Medica Scandinavica, 1983
- Ketanserin in essential hypertension: Effects during rest and exerciseEuropean Journal of Clinical Pharmacology, 1983
- Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist.BMJ, 1982
- Receptor binding profile of R 41 468, A novel antagonist at 5-HT2 receptorsLife Sciences, 1981